Focus on Anticoagulation Care

Back to articles

Investigational antidote is effective for acute major bleeding from factor Xa inhibitors

KEY POINT

Use of the investigational reversal agent andexanet alfa in patients with acute major bleeding from factor Xa inhibitors was found to decrease antifactor Xa activity and induce clinical hemostasis, according to results of the ANNEXA-4 trial published in the New England Journal of Medicine.

SOURCES

Connolly SJ, et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med. 2016;375(12):1131–41.

Hunt BJ, et al. Engineering reversal–finding an antidote for direct oral anticoagulants. N Engl J Med. 2016;375(12):1185–6.